Skip to main content
SpringerLink
Log in

Recombinant zoster vaccine preferred for older age group

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Drolet M, et al. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. CMAJ: Canadian Medical Association Journal 191: E932-E939, No. 34, 26 Aug 2019. Available from: URL: http://doi.org/10.1503/cmaj.190274

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Recombinant zoster vaccine preferred for older age group. PharmacoEcon Outcomes News 836, 23 (2019). https://doi.org/10.1007/s40274-019-6196-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6196-8

Search

Navigation